Detection of circulating CEA-IgM complexes in early stage colorectal cancer

International Journal of Biological Markers

Volumn 20, Issue 4, 2005, Pages 204-208

  Castaldi, F ^a   Marino, M ^a   Beneduce, L ^a   Belluco, C ^b   De Marchi, F ^b   Mammano, E ^b   Nitti, D ^b   Lise, M ^b   Fassina, Giorgio ^a  

^a Xeptagen SpA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biomarkers; CEA; CEA IgM immune complexes; Colon cancer

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNITY; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

EID: 30844469297     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000402     Document Type: Article

References (28)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. American Cancer Society. Cancer facts and figures. Washington, DC: American Cancer Society, 2000; 1-39.
3. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food comparison. Cancer 1986; 58: 2363-71.
4. Reddy BS. Dietary fat and its relationship to large bowel cancer. Cancer Res 1981; 41: 3700-5.
5. Hirayama T, Tannenbaum SR. Reddy BS. A large-scale cohort study on the relationship between diet and selected cancers of the digestive organs. Danbury Rep 1981; 7: 409-29.
6. Neugut AI, Jacobson JS, DeVivo I. Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993; 2: 159-76.
7. Cheach PY. Hypothesis for the aetiology of colorectal cancer: an overview. Nutr Cancer 1990; 14: 5-13.
8. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 1992; 84: 1887-96.
9. Morson BC. The evolution of colorectal carcinoma. Clin Radiol 1984; 35: 425-31.
10. Hill MJ, Morson BC, Bussey HC. Aetiology of adenoma: carcinoma sequence in large bowel. Lancet 1978; 1: 245-7.
11. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251-70.
12. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study. Ann Intern Med 1993; 118: 1-6.
13. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-7.
14. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 1572-5.
15. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-71.
16. Winawer SJ. A quarter century of colorectal cancer screening: progress and prospects. J Clin Oncol 2001; 19 (18 Suppl): 6S-12S.
17. Ransohoff DF, Sandier RS. Clinical practice. Screening for colorectal cancer. N Engl J Med 2002; 346: 40-4.
18. Gold P, Freedman S. Demonstration of tumor specific antigens in human colonic carcinoma by immunologic tolerance and absorption techniques. J Exp Med 1965; 121: 439-62.
19. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66-73.
20. Goslin R, O'Brien MJ, Steele G, et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981; 71: 246-53.
21. Filella X, Molina R, Pique JM, et al. CEA as a prognostic factor in colorectal cancer. Anticancer Res 1994; 14: 705-8.
22. Beneduce L, Castaldi F, Marino M, et al. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 2004; 19: 155-9.
23. Beneduce L, Castaldi F, Marino M, et al. Squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005; 103: 2558-65.
24. Pontisso P, Calabrese F, Benvegnù L, et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004; 90: 833-7.
25. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer 2005; 116: 579-83.
26. von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996; 16: 2325-31.
27. Habal N, Gupta RK, Bilchik AJ, Johnson T, Morton DL. TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000; 7: 352-6.
28. Boon T, Van den Eynde B. Tumour immunology. Curr Opin Immunol 2003; 15: 129-30.